ABSTRACT
Recurrent high grade glioma patients face a poor prognosis for which no curative treatment option currently exists. In contrast to prescribing high dose hypofractionated stereotactic radiotherapy (HFSRT, ≥ 6 Gyx5 in daily fractions) with debulking intent, we suggest a personalized treatment strategy to improve tumor control by delivering intermittent high dose treatment (iRT, ≥ 6 Gyx1 every six weeks). We performed a simulation analysis to compare HFSRT, iRT and iRT plus boost (≥ 6 Gyx3 in daily fractions at time of progression) based on a mathematical model of tumour growth, radiation response and patient-specific evolution of resistance to additional treatments (pembrolizumab and bevacizumab). Model parameters were fitted from tumour growth curves of 16 patients enrolled in the phase 1 NCT02313272 trial that combined HFSRT with bevacizumab and pembrolizumab. Then, iRT +/-boost treatments were simulated and compared to HFSRT based on time to tumor regrowth. The modelling results demonstrated that iRT+boost(-boost) treatment was equal or superior to HFSRT in 15(11) out of 16 cases and that patients that remained responsive to pembrolizumab and bevacizumab would benefit most from iRT. Time to progression could be prolonged through the application of additional, intermittently delivered fractions. iRT hence provides a promising treatment option for recurrent high grade glioma patients.
Competing Interest Statement
SS receives research support from Merck, Bristol Myers Squibb, and Brooklyn ImmunoTherapeutics and acts as advisory board member for Merck, and Boehringer Ingelheim. HY is on the advisory board of AbbVie and Novocure and is a member of the speaker bureau of BrainLab. HY also receives a honorarium from UpToDate. The remaining authors declare that they have no competing interests.
Clinical Trial
NCT02313272
Funding Statement
The work of this project was initiated at the 2019 Integrated Mathematical Oncology workshop at Moffitt Cancer Center for which the participation of SCB was kindly sponsored by the Moffitt Physical Sciences Oncology Center and the Integrated Mathematical Oncology Department.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All methods were carried out in accordance with relevant guidelines and regulations. The NCT02313272 (05/12/2014) was carried out at the Moffitt Cancer Center, FL between August 2015 and March 2018. All patients provided written consent and the treatment protocol and any of its amendments were approved by the institutional review board of the Moffitt Cancer Center (IRB study \#: Pro00014674 and \# 00000971).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data sets used and/or analysed in the study are available from the corresponding author on reasonable request.
